Vinati Organics Q2 FY27 Earnings Call: Announces Rs. 1,000 Cr Capex Plan, Says Worst Is Behind Us (VINATIORGA)

Vinati Organics Ltd held its Q2 FY27 earnings call on October 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Top Line Grows, Bottom Line Compresses Sharply

• Standalone Q2 FY27 net income +21% YoY to Rs.707cr (vs Rs.562cr in Q2 FY26), but EBITDA fell 27% YoY to Rs.142cr (vs Rs.195cr) and PAT fell 33% YoY to Rs.87cr (vs Rs.129cr).
• Standalone H1 FY27 net income +25% YoY to Rs.1,387cr (vs Rs.1,112cr in H1 FY26); H1 EBITDA -10% to Rs.333cr and PAT -15% to Rs.210cr.
• Consolidated Q2 FY27 net income +23% YoY to Rs.693cr (vs Rs.566cr in Q2 FY26); consolidated EBITDA -24% YoY to Rs.138cr; QoQ net income -2% vs Rs.704cr in Q1 FY27.
• Consolidated H1 FY27 net income +25% to Rs.1,398cr (vs Rs.1,115cr in H1 FY26); EBITDA -9% to Rs.318cr; PAT -15% to Rs.187cr.
• Q2 standalone net income declined 4% QoQ to Rs.681cr vs Rs.707cr in Q1 FY27, signalling sequential softening alongside the YoY margin compression.

Middle East War Costs Bite; Management Says "The Worst Is Behind Us"

• Q2 FY27 EBITDA margin of 21% was the lowest ever (flagged by analyst Surya Narayan Patra); CFO Gulshan Sakuja attributed it solely to ATBS sales shifting from Q2 into Q3 and Q4 FY27, stating "the worst is behind us."
• Ongoing Middle East war raised raw material, energy and logistics costs in Q2 FY27 — raw material increases were largely passed on to customers, but energy and logistics costs could not be fully passed through, lifting top line while hurting the bottom line.
• Logistics rates started cooling in Q3 FY27, with further reduction expected in Q4 FY27; management expects this to positively impact Q3 and Q4 FY27 profitability.
• FY27 EBITDA margin guided at ~24-25%, with the MD saying "we will end the year maybe around 24%" — below the earlier 25-30% guidance the analyst referenced.
• FY28 EBITDA margin expected at 25-26% per the CFO, versus the 26-27% the analyst noted as the company's normal aspiration.

ATBS Destocking Drags; IBB, Butylphenol and Antioxidants Deliver

• H1 FY27 revenue mix (per CFO, clarified as H1 not Q2): ATBS ~27-28% of revenue, IBP 12-15%, butylphenol 16-20%, antioxidants (AO) 15-17%.
• ATBS demand fell short of H1 FY27 expectations due to customer destocking; management expects a meaningful volume improvement with Q3 FY27 looking strong on an ATBS demand uptick, and recovery through H2 FY27.
• IBB delivered strong H1 FY27 performance on both volume and pricing, with similar performance expected in H2 FY27; IB also delivered strong H1 FY27 performance expected to continue in H2 FY27.
• Butylphenol was stable in H1 FY27 with better performance anticipated in H2 FY27 on improving demand; antioxidants delivered strong H1 FY27 despite a challenging market, with momentum expected to continue in H2 FY27 on market expansion.
• On oil & gas prices lifting ATBS demand, MD Vinati Saraf Mutneja said the impact will be visible in H2 FY27.
• Encouraging volume trends across the portfolio in Q2 FY27, with IBB, isobutylene, butylphenols and antioxidants continuing to perform well per closing commentary.

Rs.1,000cr Two-Part Capex Plan; 15-20% ROI Targeted

• Rs.500cr capex announced in Q2 FY27 to develop and commercialize new specialty chemicals for fragrances, personal care, water treatment, oil field and other applications, funded entirely through internal accruals; commercialization expected in 2 years (~FY 2028-2029).
• An additional Rs.500cr capex is being planned, with land acquisition in progress and clarity expected over the next 6 months (~April 2027, Q1 FY 2027-2028) once land acquisition and pilot trials are completed — management cautioned it "may not happen" and will be confirmed only after that review.
• ROI of 15-20% expected once projects are commissioned (~FY 2028-2029), with asset turnover of 1.0x or slightly higher — potentially 1.2x-1.5x given chemistry relatedness; no explicit margin guidance was provided for the announced capex products.
• New products are adjacencies — backward, forward or horizontal — tested over the last one year; Vinati expects to be the only producer in India for some, and second or possibly third in one segment, with 65-70% of new product sales expected to be exports and realizations averaging ~$3/kg (range ~$2-4.5/kg).
• New products expected to sustain a ~25% EBITDA margin profile, as most are "slightly more specialty products"; across the three major product segments, Vinati expects to be "fairly large" in two, while the third has other existing players.
• On execution risk, after Aditya Birla MF noted Rs.1,500cr of gross block added on a Rs.1,000cr base over the last 4 years (through FY 2026-2027), management cited pilot trials/R&D, lessons from past execution mistakes and better selection of execution agencies, saying it "hopes" commissioning and scale-up will be smoother than the previous project.

Internal Re-engineering Delays MEHQ; Revenue From Dec 2026

• MEHQ manufacturing has started at low volumes at Viral Organics, currently self-consumed for BHA production; debottlenecking is taking longer than expected, with commercial sales expected starting April 2027 (FY 2027-2028) and ~1 year to reach optimum utilization.
• CFO guided MEHQ-BHA value chain revenue at Rs.75-100cr for FY 2026-2027, explicitly stating it will not cross Rs.100cr in FY27 — the analyst noted the original ~Rs.100cr expectation for FY27 had been delayed toward FY 2027-2028.
• Management attributed the MEHQ shortfall to an internal re-engineering process, expected to be streamlined by April of FY 2027-2028 — not to the significant Chinese competition and larger capacities being added in China across the MEHQ-BHA value chain that the analyst raised.
• VOPL ramp-up guided to start April 2027 (Q1 FY 2027-2028), with about 1 year to reach desired capacity (~April 2028, FY 2028-2029); teething issues are largely behind, with another 4 months to optimum capacity (~February 2027, Q4 FY27).
• VOPL product suite revenue begins from December 2026 (Q3 FY27) — MEHQ, Guacol, Anizol, 4-methoxyacetophenone, isoamylene-based products/tertiary amyl alcohol, and PTAP (which has just started).
• MEHQ remains a high gross-margin product — management characterized current weakness as a temporary downturn, noting polymer applications (its end use) are growing.

FY27 Top-Line Guidance Intact; Rs.3,000-4,000cr Revenue Ambition

• FY27 guidance: management expects to end FY 2027 with 20-25% improvement in top line over FY26, driven by improvement in volumes as well as pricing — though ATBS demand did not pick up as anticipated at the start of FY27, impacting the H1 target.
• Revenue plan of Rs.3,000-4,000cr over the next 2 to 3 years (i.e., by FY 2029-2030), of which MEHQ is expected to contribute only Rs.100cr.
• Better volumes and prices for ATBS expected in Q3-Q4 FY27 and FY 2027-2028, alongside the logistics cost relief expected to benefit Q3 and Q4 FY27 profitability.
• VOPL expected to contribute meaningfully to consolidated top and bottom line after process re-engineering completes for a few products (timeline unspecified).
• MD Vinati Saraf Mutneja acknowledged the soft Q2 FY27 outcome but pointed to encouraging volumes, investment in new specialty chemical opportunities, and a stated focus on profitable growth, disciplined capital allocation and long-term value creation.